<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>1.25-dihydroxy-<z:chebi fb="0" ids="28940">vitamin D3</z:chebi> (1.25 (OH)2D3) was tested in seven patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The study was undertaken because 1.25 (OH)2D3 promotes differentiating myeloid cells in vitro and because of a prior report of potential benefit in a clinical study </plain></SENT>
<SENT sid="2" pm="."><plain>The drug was given orally at a dose of 2.5 micrograms/day for a minimum of 8 weeks (range 8-28) </plain></SENT>
<SENT sid="3" pm="."><plain>After therapy, there were no significant changes in any of the parameters observed in peripheral blood or bone marrow </plain></SENT>
<SENT sid="4" pm="."><plain>We did not observe any feature of granulocytic-monocytic differentiation </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment was well tolerated </plain></SENT>
<SENT sid="6" pm="."><plain>One patient died because of <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Survivors have persisting <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and continue to be transfusion dependent </plain></SENT>
<SENT sid="8" pm="."><plain>1.25 (OH)2D3 has no beneficial effect in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> with this dose regimen </plain></SENT>
</text></document>